RitsukoIwanagaRitsuko Iwanaga39.74403510000000-104.836059400000002349Iwanaga, RitsukoResearch Associateprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:address2address line 2vivo:address3address line 3vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonAuthorship 815924Authorship 86851125358638Wang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HLBreast cancer research : BCRWang CA, Harrell JC, Iwanaga R, Jedlicka P, Ford HL. Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3. Breast Cancer Res. 2014 Oct 30; 16(5):462.Breast Cancer Res2014-10-30T00:00:002014Vascular endothelial growth factor C promotes breast cancer progression via a novel antioxidant mechanism that involves regulation of superoxide dismutase 3.Authorship 1232963Authorship 134106326201719Kitamura H, Ozono E, Iwanaga R, Bradford AP, Okuno J, Shimizu E, Kurayoshi K, Kugawa K, Toh H, Ohtani KGenes to cells : devoted to molecular & cellular mechanismsKitamura H, Ozono E, Iwanaga R, Bradford AP, Okuno J, Shimizu E, Kurayoshi K, Kugawa K, Toh H, Ohtani K. Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts. Genes Cells. 2015 Sep; 20(9):739-57.Genes Cells2015-07-23T00:00:002015Identification of novel target genes specifically activated by deregulated E2F in human normal fibroblasts.LoriSusselLori Gail Sussel39.74404140000000-104.8383945000000011200Sussel, LoriProfessorAuthorship 153560427888102Kurayoshi K, Okuno J, Ozono E, Iwanaga R, Bradford AP, Kugawa K, Araki K, Ohtani KBiochemical and biophysical research communicationsKurayoshi K, Okuno J, Ozono E, Iwanaga R, Bradford AP, Kugawa K, Araki K, Ohtani K. The phosphatidyl inositol 3 kinase pathway does not suppress activation of the ARF and BIM genes by deregulated E2F1 activity. Biochem Biophys Res Commun. 2017 Jan 22; 482(4):784-790.Biochem Biophys Res Commun2016-11-22T00:00:002016The phosphatidyl inositol 3 kinase pathway does not suppress activation of the ARF and BIM genes by deregulated E2F1 activity.BenjaminBitlerBenjamin Guy Bitler39.74403280000000-104.8408104000000012331Bitler, BenjaminAssociate ProfessorAuthorship 155271428042030Kurayoshi K, Shiromoto A, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani KBiochemical and biophysical research communicationsKurayoshi K, Shiromoto A, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani K. Ectopic expression of the CDK inhibitor p21Cip1 enhances deregulated E2F activity and increases cancer cell-specific cytotoxic gene expression mediated by the ARF tumor suppressor promoter. Biochem Biophys Res Commun. 2017 01 29; 483(1):107-114.Biochem Biophys Res Commun2016-12-29T00:00:002016Ectopic expression of the CDK inhibitor p21Cip1 enhances deregulated E2F activity and increases cancer cell-specific cytotoxic gene expression mediated by the ARF tumor suppressor promoter.Authorship 157378127091643Iwanaga R, Orlicky DJ, Arnett J, Guess MK, Hurt KJ, Connell KAInternational urogynecology journalIwanaga R, Orlicky DJ, Arnett J, Guess MK, Hurt KJ, Connell KA. Comparative histology of mouse, rat, and human pelvic ligaments. Int Urogynecol J. 2016 Nov; 27(11):1697-1704.Int Urogynecol J2016-04-18T00:00:002016Comparative histology of mouse, rat, and human pelvic ligaments.5Other Faculty1Professor3Asst Professor2Assoc Professor4Instructor16211008Komori H, Enomoto M, Nakamura M, Iwanaga R, Ohtani KThe EMBO journalKomori H, Enomoto M, Nakamura M, Iwanaga R, Ohtani K. Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. EMBO J. 2005 Nov 02; 24(21):3724-36.EMBO J2005-10-06T00:00:002005Distinct E2F-mediated transcriptional program regulates p14ARF gene expression.19077036Ozono E, Komori H, Iwanaga R, Ikeda MA, Iseki S, Ohtani KGenes to cells : devoted to molecular & cellular mechanismsOzono E, Komori H, Iwanaga R, Ikeda MA, Iseki S, Ohtani K. E2F-like elements in p27(Kip1) promoter specifically sense deregulated E2F activity. Genes Cells. 2009 Jan; 14(1):89-99.Genes Cells2008-12-10T00:00:002008E2F-like elements in p27(Kip1) promoter specifically sense deregulated E2F activity.12631 East 17th Avenue2AO1Academic Office 112631 East 17th AvenueAurora80045-2527CO15467751Iwanaga R, Komori H, Ohtani KOncogeneIwanaga R, Komori H, Ohtani K. Differential regulation of expression of the mammalian DNA repair genes by growth stimulation. Oncogene. 2004 Nov 11; 23(53):8581-90.Oncogene2004-11-11T00:00:002004Differential regulation of expression of the mammalian DNA repair genes by growth stimulation.15629899Matsumura-Arioka Y, Ohtani K, Hara T, Iwanaga R, Nakamura MInternational immunologyMatsumura-Arioka Y, Ohtani K, Hara T, Iwanaga R, Nakamura M. Identification of two distinct elements mediating activation of telomerase (hTERT) gene expression in association with cell growth in human T cells. Int Immunol. 2005 Feb; 17(2):207-15.Int Immunol2005-01-03T00:00:002005Identification of two distinct elements mediating activation of telomerase (hTERT) gene expression in association with cell growth in human T cells.19726883McCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HLThe Journal of clinical investigationMcCoy EL, Iwanaga R, Jedlicka P, Abbey NS, Chodosh LA, Heichman KA, Welm AL, Ford HL. Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition. J Clin Invest. 2009 Sep; 119(9):2663-77.J Clin Invest2009-08-24T00:00:002009Six1 expands the mouse mammary epithelial stem/progenitor cell pool and induces mammary tumors that undergo epithelial-mesenchymal transition.22333994Qamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht KGynecologic oncologyQamar L, Deitsch E, Patrick AN, Post MD, Spillman MA, Iwanaga R, Thorburn A, Ford HL, Behbakht K. Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer. Gynecol Oncol. 2012 May; 125(2):451-7.Gynecol Oncol2012-02-12T00:00:002012Specificity and prognostic validation of a polyclonal antibody to detect Six1 homeoprotein in ovarian cancer.22702391Ozono E, Komori H, Iwanaga R, Tanaka T, Sakae T, Kitamura H, Yamaoka S, Ohtani KGenes to cells : devoted to molecular & cellular mechanismsOzono E, Komori H, Iwanaga R, Tanaka T, Sakae T, Kitamura H, Yamaoka S, Ohtani K. Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts. Genes Cells. 2012 Aug; 17(8):660-72.Genes Cells2012-06-15T00:00:002012Tumor suppressor TAp73 gene specifically responds to deregulated E2F activity in human normal fibroblasts.Authorship 182257529855511Komori H, Goto Y, Kurayoshi K, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani KScientific reportsKomori H, Goto Y, Kurayoshi K, Ozono E, Iwanaga R, Bradford AP, Araki K, Ohtani K. Differential requirement for dimerization partner DP between E2F-dependent activation of tumor suppressor and growth-related genes. Sci Rep. 2018 05 31; 8(1):8438.Sci Rep2018-05-31T00:00:002018Differential requirement for dimerization partner DP between E2F-dependent activation of tumor suppressor and growth-related genes.CharlesSagerstromCharles Greger Sagerstrom39.74403510000000-104.8360594000000015262Sagerstrom, CharlesProfessorD00007446210250.973904Positive Regulatory Domain I-Binding Factor 1D015972Physiology35311830.651116Gene Expression Regulation, NeoplasticSOM-BDC Basic ResearchSOM-OB/GYN RS GENERAL OPSEMERGENCY MEDJaneStremmingJane Elizabeth Stremming39.74403510000000-104.8360594000000015639Stremming, JaneAsst ProfessorD008544Anatomy27680.933972MelanocytesD050687Chemicals & Drugs17560.972109E2F1 Transcription FactorD029961Chemicals & Drugs682840.779739Zebrafish ProteinsSOM-PHARM General OperationsSDM-Craniofacial BiologySDM-Dental Clinic Clincl AffrsSDM-Dept Restorative DentistrySOM-PathologySOM-PEDSDevl BiologyNeonatologyEndocrinologyUniversity of Colorado Denver - Anschutz Medical CampusCliffordLitvakClifford S Litvak39.74403510000000-104.836059400000001149Litvak, CliffordAssoc Professor-ClinicalDavidOrlickyDavid J Orlicky39.74545800000000-104.839369100000001404Orlicky, DavidAssociate ProfessorKristinArtingerKristin Bruk Artinger39.74403510000000-104.836059400000001778Artinger, KristinElectronic Research AdminHeideFordHeide L Ford39.74545800000000-104.839369100000001534Ford, HeideProfessor1.245180.00356848153research areas0.7700360.026973422coauthor of13.33953.156460similar to1121selected publicationsBruceAppelBruce H Appel39.74403510000000-104.836059400000003093Appel, BruceProfessorAndrewBradfordAndrew Peter Bradford39.74403280000000-104.8408104000000036Bradford, AndrewProfessorMeganKelseyMegan Moriarty Kelsey39.74403510000000-104.836059400000002285Kelsey, MeganProfessorChristopherCousarChristopher L Cousar39.74403510000000-104.836059400000003519Cousar, ChristopherSenior InstructorLonnieJohnsonLonnie R Johnson39.74403510000000-104.83605940000000915Johnson, LonnieProfessorAuthorship 221929132562448Iwanaga R, Truong BT, Hsu JY, Lambert KA, Vyas R, Orlicky D, Shellman YG, Tan AC, Ceol C, Artinger KBMolecular carcinogenesisIwanaga R, Truong BT, Hsu JY, Lambert KA, Vyas R, Orlicky D, Shellman YG, Tan AC, Ceol C, Artinger KB. Loss of prdm1a accelerates melanoma onset and progression. Mol Carcinog. 2020 09; 59(9):1052-1063.Mol Carcinog2020-06-20T00:00:002020Loss of prdm1a accelerates melanoma onset and progression.Authorship 193153Authorship 277289836833320Nakajima R, Zhao L, Zhou Y, Shirasawa M, Uchida A, Murakawa H, Fikriyanti M, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani KGenesNakajima R, Zhao L, Zhou Y, Shirasawa M, Uchida A, Murakawa H, Fikriyanti M, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani K. Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool. Genes (Basel). 2023 02 02; 14(2).Genes (Basel)2023-02-02T00:00:002023Deregulated E2F Activity as a Cancer-Cell Specific Therapeutic Tool.Authorship 277669636865165Nguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, Jeong AD, Guntupalli SR, Behbakht K, Gbaja V, Arnoult N, Chuong EB, Bitler BGbioRxiv : the preprint server for biologyNguyen LL, Watson ZL, Ortega R, Woodruff ER, Jordan KR, Iwanaga R, Yamamoto TM, Bailey CA, Jeong AD, Guntupalli SR, Behbakht K, Gbaja V, Arnoult N, Chuong EB, Bitler BG. Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models. bioRxiv. 2023 Feb 23.bioRxiv2023-02-23T00:00:002023Combinatory EHMT and PARP inhibition induces an interferon response and a CD8 T cell-dependent tumor regression in PARP inhibitor-resistant models.Authorship 2828791237141667Nakajima R, Deguchi R, Komori H, Zhao L, Zhou Y, Shirasawa M, Angelina A, Goto Y, Tohjo F, Nakahashi K, Nakata K, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani KBiochemical and biophysical research communicationsNakajima R, Deguchi R, Komori H, Zhao L, Zhou Y, Shirasawa M, Angelina A, Goto Y, Tohjo F, Nakahashi K, Nakata K, Iwanaga R, Bradford AP, Araki K, Warita T, Ohtani K. The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F. Biochem Biophys Res Commun. 2023 06 30; 663:154-162.Biochem Biophys Res Commun2023-04-25T00:00:002023The TFDP1 gene coding for DP1, the heterodimeric partner of the transcription factor E2F, is a target of deregulated E2F.Authorship 284840737243607Brubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BGExpert opinion on therapeutic targetsBrubaker LW, Backos DS, Nguyen VT, Reigan P, Yamamoto TM, Woodruff ER, Iwanaga R, Wempe MF, Kumar V, Persenaire C, Watson ZL, Bitler BG. Novel chromobox 2 inhibitory peptide decreases tumor progression. Expert Opin Ther Targets. 2023 Apr-May; 27(4-5):361-371.Expert Opin Ther Targets2023-05-27T00:00:002023Novel chromobox 2 inhibitory peptide decreases tumor progression.Authorship 268112true1ProfessorProfessortrue1ProfessorProfessortrue1Asst ProfessorAsst Professortrue1ProfessorProfessortrue1Senior InstructorSenior InstructorAuthorship 296903638132337Zhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Zhao L, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani KBiologyZhou Y, Nakajima R, Shirasawa M, Fikriyanti M, Zhao L, Iwanaga R, Bradford AP, Kurayoshi K, Araki K, Ohtani K. Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression. Biology (Basel). 2023 Dec 11; 12(12).Biology (Basel)2023-12-11T00:00:002023Expanding Roles of the E2F-RB-p53 Pathway in Tumor Suppression.true1Electronic Research AdminElectronic Research Admintrue1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1ProfessorProfessortrue1Research AssociateResearch Associatetrue1Associate ProfessorAssociate Professortrue1Assoc Professor-ClinicalAssoc Professor-ClinicalAuthorship 421786Authorship 112656122765220Iwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HLBreast cancer research : BCRIwanaga R, Wang CA, Micalizzi DS, Harrell JC, Jedlicka P, Sartorius CA, Kabos P, Farabaugh SM, Bradford AP, Ford HL. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways. Breast Cancer Res. 2012 Jul 05; 14(4):R100.Breast Cancer Res2012-07-05T00:00:002012Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.Authorship 645943Authorship 113607324893334Kurayoshi K, Ozono E, Iwanaga R, Bradford AP, Komori H, Ohtani KBiochemical and biophysical research communicationsKurayoshi K, Ozono E, Iwanaga R, Bradford AP, Komori H, Ohtani K. Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs. Biochem Biophys Res Commun. 2014 Jul 18; 450(1):240-6.Biochem Biophys Res Commun2014-06-02T00:00:002014Cancer cell specific cytotoxic gene expression mediated by ARF tumor suppressor promoter constructs.Authorship 665414